Pages that link to "Item:Q3576929"
From MaRDI portal
The following pages link to A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials (Q3576929):
Displaying 21 items.
- A causal framework for surrogate endpoints with semi-competing risks data (Q712513) (← links)
- Binary surrogates with stratified samples when weights are unknown (Q2418066) (← links)
- Exploiting multiple outcomes in Bayesian principal stratification analysis with application to the evaluation of a job training program (Q2441865) (← links)
- Adaptive neural network surrogate model for solving the implied volatility of time-dependent American option via Bayesian inference (Q2696739) (← links)
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials (Q2792764) (← links)
- An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference (Q2827172) (← links)
- Design and estimation for evaluating principal surrogate markers in vaccine trials (Q2846433) (← links)
- A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials (Q2893404) (← links)
- Comparing biomarkers as principal surrogate endpoints (Q2893405) (← links)
- Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework (Q2912363) (← links)
- Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials (Q3076045) (← links)
- On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints (Q3465713) (← links)
- A Bayesian Approach to Improved Estimation of Causal Effect Predictiveness for a Principal Surrogate Endpoint (Q4649074) (← links)
- A Multiple Imputation Approach for the Evaluation of Surrogate Markers in the Principal Stratification Causal Inference Framework (Q4984852) (← links)
- Identification of causal effects in the presence of nonignorable missing outcome values (Q5170195) (← links)
- Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker (Q5222223) (← links)
- Discussion on ``Surrogate measures and consistent surrogates'' (Q5891277) (← links)
- Solutions for Surrogacy Validation with Longitudinal Outcomes for a Gene Therapy (Q6055756) (← links)
- Testing for Heterogeneity in the Utility of a Surrogate Marker (Q6079768) (← links)
- Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials (Q6636037) (← links)
- Principal quantile treatment effect estimation using principal scores (Q6656329) (← links)
